Understanding HIV/AIDS: How the Virus Attacks the Immune System

HIV (Human Immunodeficiency Virus) is a lentivirus that targets CD4+ T helper cells, progressively dismantling cell-mediated immunity. Without treatment, it advances through three stages to AIDS (Acquired Immunodeficiency Syndrome).

Natural History Stages

1. Acute HIV Infection (Seroconversion Syndrome)

  • Timing: 2–6 weeks post-exposure.
  • Symptoms (40–90%): Fever, maculopapular rash, pharyngitis, lymphadenopathy, myalgia, headache, meningitis, ulcerative esophagitis.
  • Virology: Massive viremia (millions copies/mL); high transmission risk.
  • Diagnosis: HIV RNA PCR or p24 antigen positive; antibody negative/indeterminate.

2. Chronic HIV (Clinical Latency)

  • Duration: Years to decades (median ~10 years untreated).
  • Clinical: Asymptomatic or persistent generalized lymphadenopathy (PGL).
  • Immunology: Gradual CD4+ decline (~50–80 cells/µL/year); ongoing viral replication in lymphoid tissue.
  • Transmission: Possible at all stages; risk correlates with viral load.

3. AIDS (Advanced HIV Disease)

  • Definition: CD4+ <200 cells/µL OR AIDS-defining illness (regardless of CD4).
  • Opportunistic Infections (OIs):
    • PCP (Pneumocystis pneumonia)
    • TB (pulmonary/extrapulmonary)
    • Cryptococcal meningitis
    • Toxoplasma encephalitis
    • Cytomegalovirus (retinitis, colitis)
    • MAC (Mycobacterium avium complex)
    • Esophageal candidiasis, chronic herpes simplex
  • Malignancies: Kaposi sarcoma (HHV-8), NHL (EBV-driven), cervical/anal cancer (HPV), hepatocellular carcinoma (HBV/HCV coinfection).
  • Neurocognitive: HAND (HIV-associated neurocognitive disorder): asymptomatic → mild → HIV dementia.
  • Wasting Syndrome: >10% weight loss + diarrhea/fever/weakness >30 days.

Systemic Effects of HIV

SystemKey Manifestations
ImmuneCD4+ depletion, inverted CD4:CD8, B-cell hyperactivation, impaired vaccine response
CardiovascularAccelerated atherosclerosis, myocarditis, cardiomyopathy
RenalHIVAN (focal segmental glomerulosclerosis), tenofovir nephrotoxicity
HepaticCoinfection HBV/HCV progression, drug-induced liver injury
BoneOsteoporosis, osteonecrosis (AVN)
MetabolicInsulin resistance, lipodystrophy (older ART), dyslipidemia

Antiretroviral Therapy (ART) — Game Changer

  • Goal: Sustained viral suppression (<50 copies/mL) → immune reconstitution, near-normal life expectancy, zero sexual transmission (U=U).
  • Regimens: 2–3 drug combinations (INSTI + 2 NRTIs preferred). Single-tablet regimens available.
  • Monitoring: Viral load, CD4, renal/hepatic/lipid panels, resistance testing if failure.

Early diagnosis + immediate ART = best outcomes. CDC recommends universal screening ages 13–64; PrEP for high-risk negatives.

HIV & AIDS - Related Articles